Epstein Becker Green participated as health regulatory counsel on the $2.6 billion acquisition of Sepracor Inc. by Dainippon Sumitomo Pharma Co., Ltd. of Japan (DSP). EBG partners Robert D. Reif and Wendy C . Goldstein led the EBG team, providing health regulatory advice and due diligence to DSP on the transaction.
DSP is one of the largest pharmaceutical companies in Japan. Sepracor Inc. is a specialty pharmaceutical provider based in Marlborough, Massachusetts.